Veroniki AA, Antony J, Straus SE, Ashoor HM, Finkelstein Y, Khan PA et al. Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs. PLoS One. 2018;13(6):e0198447.

Williams PL, Crain MJ, Yildirim C, Hazra R, Van Dyke RB, Rich K et al. Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants. JAMA Pediatr. 2015;169(1):48-55.

Sibiude J, Mandelbrot L, Blanche S, Le Chenadec J, Boullag-Bonnet N, Faye A et al. Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11). PLoS Med. 2014;11(4):e1001635.

Alemu FM, Yalew AW. Does antiretroviral therapy cause congenital malformations? A systematic review and meta-analysis. Epidemiol Health. 2021;43:e2021008.

Saint-Lary L, Benevent J, Damase-Michel C, Vayssière C, Leroy V, Sommet A. Adverse perinatal outcomes associated with prenatal exposure to protease-inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based antiretroviral combinations in pregnant women with HIV infection: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2023;23(1):80.

Cowdell I, Beck K, Portwood C, Sexton H, Kumarendran M, Brandon Z et al. Adverse perinatal outcomes associated with protease inhibitor-based antiretroviral therapy in pregnant women living with HIV: A systematic review and meta-analysis. EClinicalMedicine. 2022;46:101368.

Sirois PA, Huo Y, Williams PL, Malee K, Garvie PA, Kammerer B et al. Safety of perinatal exposure to antiretroviral medications: developmental outcomes in infants. Pediatr Infect Dis J. 2013;32(6):648-55.

Wedderburn CJ, Weldon E, Bertran-Cobo C, Rehman AM, Stein DJ, Gibb DM et al. Early neurodevelopment of HIV-exposed uninfected children in the era of antiretroviral therapy: a systematic review and meta-analysis. Lancet Child Adolesc Health. 2022;6(6):393-408.

Caniglia EC, Patel K, Huo Y, Williams PL, Kapetanovic S, Rich KC et al. Atazanavir exposure in utero and neurodevelopment in infants: a comparative safety study. AIDS. 2016;30(8):1267-78.

Rowe K, Buivydaite R, Heinsohn T, Rahimzadeh M, Wagner RG, Scerif G et al. Executive function in HIV-affected children and adolescents: a systematic review and meta-analyses. AIDS Care. 2021;33(7):833-857.

Janssen-Cilag. Edurant Produktresumé. EMA [www]. [cited 2025-01-17].

Patel P, Ford SL, Baker M, Meyer C, Garside L, D'Amico R et al. Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials. HIV Med. 2023;24(5):568-579.

The Antiretroviral Pregnancy Registry Interim Report. The Antiretroviral Pregnancy Registry [www]. [updated 2024-06-01, cited 2024-09-25].

Referensgruppen för Antiviral Terapi (RAV). Profylax och behandling av hivinfektion vid graviditet, 2024. Svenska Läkarsällskapet [www]. [cited 2024-09-25].

Veroniki AA, Antony J, Straus SE, Ashoor HM, Finkelstein Y, Khan PA et al. Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs. PLoS One. 2018;13(6):e0198447.

Williams PL, Crain MJ, Yildirim C, Hazra R, Van Dyke RB, Rich K et al. Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants. JAMA Pediatr. 2015;169(1):48-55.

Sibiude J, Mandelbrot L, Blanche S, Le Chenadec J, Boullag-Bonnet N, Faye A et al. Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11). PLoS Med. 2014;11(4):e1001635.

Alemu FM, Yalew AW. Does antiretroviral therapy cause congenital malformations? A systematic review and meta-analysis. Epidemiol Health. 2021;43:e2021008.

Saint-Lary L, Benevent J, Damase-Michel C, Vayssière C, Leroy V, Sommet A. Adverse perinatal outcomes associated with prenatal exposure to protease-inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based antiretroviral combinations in pregnant women with HIV infection: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2023;23(1):80.

Cowdell I, Beck K, Portwood C, Sexton H, Kumarendran M, Brandon Z et al. Adverse perinatal outcomes associated with protease inhibitor-based antiretroviral therapy in pregnant women living with HIV: A systematic review and meta-analysis. EClinicalMedicine. 2022;46:101368.

Sirois PA, Huo Y, Williams PL, Malee K, Garvie PA, Kammerer B et al. Safety of perinatal exposure to antiretroviral medications: developmental outcomes in infants. Pediatr Infect Dis J. 2013;32(6):648-55.

Wedderburn CJ, Weldon E, Bertran-Cobo C, Rehman AM, Stein DJ, Gibb DM et al. Early neurodevelopment of HIV-exposed uninfected children in the era of antiretroviral therapy: a systematic review and meta-analysis. Lancet Child Adolesc Health. 2022;6(6):393-408.

Caniglia EC, Patel K, Huo Y, Williams PL, Kapetanovic S, Rich KC et al. Atazanavir exposure in utero and neurodevelopment in infants: a comparative safety study. AIDS. 2016;30(8):1267-78.

Rowe K, Buivydaite R, Heinsohn T, Rahimzadeh M, Wagner RG, Scerif G et al. Executive function in HIV-affected children and adolescents: a systematic review and meta-analyses. AIDS Care. 2021;33(7):833-857.

ViiV Healthcare BV. Tivicay Produktresumé. EMA [www]. [cited 2025-01-17].

Lewis JM, Railton E, Riordan A, Khoo S, Chaponda M. Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing. AIDS. 2016;30:1313-5.

Ikumi NM, Anumba D, Matjila M. Pharmacokinetics and placental transfer of dolutegravir in pregnancy. J Antimicrob Chemother. 2021.

EMA. New study suggests risk of birth defects in babies born to women on HIV medicine dolutegravir. EMA [www]. [updated 2018-05-18, cited 2025-01-17].

Zash R, Holmes L, Diseko M, Jacobson DL, Brummel S, Mayondi G et al. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana. N Engl J Med. 2019;381(9):827-840.

Raesima MM, Ogbuabo CM, Thomas V, Forhan SE, Gokatweng G, Dintwa E et al. Dolutegravir Use at Conception - Additional Surveillance Data from Botswana. N Engl J Med. 2019;381(9):885-887.

Pereira GFM, Kim A, Jalil EM, Fernandes Fonseca F, Shepherd BE, Veloso VG et al. Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study. Lancet HIV. 2021;8(1):e33-e41.

Vannappagari V, Thorne C, for APR and EPPICC. Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir. J Acquir Immune Defic Syndr. 2019;81(4):371-378.

Money D, Lee T, O'Brien C, Brophy J, Bitnun A, Kakkar F et al. Congenital anomalies following antenatal exposure to dolutegravir: a Canadian surveillance study. BJOG. 2019;126(11):1338-1345.

Payra S, Harsha D, Kumar K, Manjhi PK, Singh S, Kumar R et al. Risk of Congenital Anomalies with Dolutegravir-Based Anti-retroviral Regimens: A Systematic Review and Meta-analysis. Clin Drug Investig. 2024;44(9):667-685.

WHO. UPDATE OF RECOMMENDATIONS ON FIRST- AND SECOND-LINE ANTIRETROVIRAL REGIMENS. WHO [www]. [updated 2019-07-01, cited 2025-01-17].

Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Clinicalinfohivcom [www]. [updated 2024-12-19, cited 2025-01-17].